COMMUNIQUÉS West-GlobeNewswire

-
RadNet to Make its Second Acquisition in Houston, Texas
10/04/2024 -
Medicines360 Appoints Erica Rogers to Board of Directors
10/04/2024 -
ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa
10/04/2024 -
EFA Technologies, pioneer in portable blood labs, enters Brazilian market after Anvisa approval of its portable RevDx device
10/04/2024 -
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
10/04/2024 -
Philips Respironics reaches agreement with US government on a consent decree creating a clear path forward
10/04/2024 -
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
10/04/2024 -
Mobile-health Network Solutions Announces Pricing of $9 Million Initial Public Offering
10/04/2024 -
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
09/04/2024 -
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
09/04/2024 -
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
09/04/2024 -
Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting
09/04/2024 -
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
09/04/2024 -
Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024
09/04/2024 -
Dentsply Sirona to Host First Quarter Conference Call on May 2nd
09/04/2024 -
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
09/04/2024 -
Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting
09/04/2024 -
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
09/04/2024 -
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
09/04/2024
Pages